PTIE Share Price

Open 0.68 Change Price %
High 0.73 1 Day 0.02 3.08
Low 0.64 1 Week 0.09 15.52
Close 0.67 1 Month 0.02 3.08
Volume 1265695 1 Year -1.21 -64.36
52 Week High 3.00
52 Week Low 0.00
PTIE Important Levels
Resistance 2 0.75
Resistance 1 0.72
Pivot 0.68
Support 1 0.62
Support 2 0.59
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ETRM 0.07 0.00%
AAPL 113.86 1.55%
AAPL 113.86 1.55%
More..
NASDAQ USA Top Gainers Stocks
HTCO 11.00 62.96%
LOCM 0.09 50.00%
OPXA 1.21 40.70%
QKLS 0.18 38.46%
ZAZA 0.08 33.33%
MOSY 0.46 31.43%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
PPHM 0.40 25.00%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
BGMD 0.05 -37.50%
More..

Pain Therapeutics (NASDAQ: PTIE)

PTIE Technical Analysis 5
As on 9th Dec 2016 PTIE Share Price closed @ 0.67 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 1.86 & Strong Sell for SHORT-TERM with Stoploss of 0.75 we also expect STOCK to react on Following IMPORTANT LEVELS.
PTIE Target for December
1st Target up-side 0.82
2nd Target up-side 0.95
3rd Target up-side 1.07
1st Target down-side 0.46
2nd Target down-side 0.33
3rd Target down-side 0.21
PTIE Other Details
Segment EQ
Market Capital 136600464.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.paintrials.com
PTIE Address
PTIE
7801 N Capital of Texas Highway
Suite 260
Austin, TX 78731
United States
Phone: 512-501-2444
Fax: 512-614-0414
PTIE Latest News
Interactive Technical Analysis Chart Pain Therapeutics ( PTIE NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Pain Therapeutics
PTIE Business Profile
Pain Therapeutics, Inc. is a biopharmaceutical company that develops drugs. The Company has four drug candidates in clinical programs, including REMOXY, abuse-resistant hydromorphone, abuse-resistant hydrocodone and a radio-labeled monoclonal antibody to treat metastatic melanoma. It is also working on a new treatment for patients with hemophilia. It has collaboration agreement with King Pharmaceuticals, Inc. (King) develops and commercializes REMOXY and other opioid painkillers. The Company and King jointly managed a Phase III clinical program and New Drug Application (NDA) submission for REMOXY. It is also developing a pipeline of drug candidates in the area of oncology and hematology. It owns all commercial rights to its pipeline of drug candidates in oncology and hematology. As of December 31, 2010, it leased approximately 30,700 square feet of space in San Mateo, California and all of its operations are located in San Mateo.